The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling

Circulation

Volumn 113, Issue 7, 2006, Pages 995-1004

  Zhao, Wen ^a   Yuan, Qunying ^a   Qian, Jiang ^a   Waggoner, Jason R ^a   Pathak, Anand ^a   Chu, Guoxiang ^a   Mitton, Bryan ^a   Sun, Xiaoyin ^a   Jin, Jay ^a   Braz, Julian C ^a   Hahn, Harvey S ^a   Marreez, Yehia ^a   Syed, Faisal ^a   Pollesello, Piero ^b   Annila, Arto ^c   Wang, Hong Sheng ^a   Schultz, Jo El J ^a   Molkentin, Jeffery D ^a   Liggett, Stephen B ^a   Dorn, Gerald W ^a   Kranias, Evangelia G ^a   more..

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Cardiovascular Research   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Contractility; Hypertrophy; Myocytes; Phospholamban; Sarcoplasmic reticulum

Indexed keywords

ASPARAGINE; CALCIUM CHANNEL L TYPE; CALCIUM ION; CALSEQUESTRIN; ISOPRENALINE; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLAMBAN; PROTEIN; PROTEIN KINASE B; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM ADENOSINE TRIPHOSPHATASE 2; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE (CALCIUM); ARGININE; ATP2A2 PROTEIN, HUMAN; ATP2A2 PROTEIN, MOUSE; CALCIUM; CALCIUM BINDING PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CALCIUM MOBILIZATION; CONFORMATION; CONTROLLED STUDY; ENZYME INHIBITION; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM; STATISTICAL SIGNIFICANCE; UPREGULATION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; CARDIOMEGALY; DRUG ANTAGONISM; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ARGININE; CALCIUM; CALCIUM-BINDING PROTEINS; CALCIUM-TRANSPORTING ATPASES; CARDIOMEGALY; HUMANS; KINETICS; LYSINE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SPECIES SPECIFICITY;

EID: 33645085618     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.583351     Document Type: Article

References (29)

1. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol. 1997;92(suppl 1):87-93.
2. Houser SR, Piacentino V III, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol. 2000;32:1595-1607.
3. 2+-ATPase in a rat model of heart failure. Circulation. 2001;104:1424-1429.
4. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002;105:904-907.
5. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-577.
6. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410-1413.
7. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW II, MacLennan DH, Kremastinos DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111:869-876.
8. 2+-ATPase. Proc Natl Acad Sci U S A. 2003;100:467-472.
9. 2+-ATPase isoform of cardiac sarcoplasmic reticulum. J Biol Chem. 1998;273:14238-14241.
10. Zhai J, Schmidt AG, Hoit BD, Kimura Y, MacLennan DH, Kranias EG. Cardiac-specific overexpression of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo. J Biol Chem. 2000;275:10538-10544.
11. Hoit BD, Khoury SF, Kranias EG, Ball N, Walsh RA. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 1995;77:632-637.
12. Zhao W, Frank KF, Chu G, Gerst MJ, Schmidt AG, Ji Y, Periasamy M, Kranias EG. Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state. Cardiovasc Res. 2003;57:71-81.
13. Chu G, Dorn GW II, Luo W, Harrer JM, Kadambi VJ, Walsh RA, Kranias EG. Monomeric phospholamban overexpression in transgenic mouse hearts. Circ Res. 1997;81:485-492.
14. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn GW II, MacLennan DH, Kranias EG. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem. 2001;276:24145-24152.
15. Zvaritch E, Backx PH, Jirik F, Kimura Y, de Leon S, Schmidt AG, Hoit BD, Lester JW, Kranias EG, MacLennan DH. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility. J Biol Chem. 2000;275:14985-14991.
16. Pollesello P, Annila A, Ovaska M. Structure of the 1-36 amino-terminal fragment of human phospholamban by nuclear magnetic resonance and modeling of the phospholamban pentamer. Biophys J. 1999;76:1784-1795.
17. 2+ uptake as a primary cause of heart failure. Cardiovasc Res. 2002;56:248-259.
18. Liang Q, Molkentin JD. Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol. 2003;35:1385-1394.
19. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004;63:467-475.
20. Sugden PH. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res. 2003;93:1179-1192.
21. Mortishire-Smith RJ, Pitzenberger SM, Burke CJ, Middaugh CR, Garsky VM, Johnson RG. Solution structure of the cytoplasmic domain of phospholamban: phosphorylation leads to a local perturbation in secondary structure. Biochemistry. 1995;34:7603-7613.
22. Fujii J, Zarain-Herzberg A, Willard HF, Tada M, MacLennan DH. Structure of the rabbit phospholamban gene, cloning of the human cDNA, and assignment of the gene to human chromosome 6. J Biol Chem. 1991;266:11669-11675.
23. 15N heteronuclear NMR spectroscopy shows four dynamic domains for phospholamban reconstituted in dodecylphosphocholine micelles. Biophys J. 2004;87:1205-1214.
24. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW II, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 1996;97:533-539.
25. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205.
26. 2+ content in isolated failing and nonfailing human myocardium. Circ Res. 1999;85:38-46.
27. Zhao W, Uehara Y, Chu G, Song Q, Qian J, Young K, Kranias EG. Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. J Mol Cell Cardiol. 2004;37:607-612.
28. Bluhm WF, Kranias EG, Dillmann WH, Meyer M. Phospholamban: a major determinant of the cardiac force-frequency relationship. Am J Physiol Heart Circ Physiol. 2000;278:H249-H255.
29. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 2003;111:1475-1486.